AR037490A1 - Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos - Google Patents
Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentosInfo
- Publication number
- AR037490A1 AR037490A1 ARP020102073A ARP020102073A AR037490A1 AR 037490 A1 AR037490 A1 AR 037490A1 AR P020102073 A ARP020102073 A AR P020102073A AR P020102073 A ARP020102073 A AR P020102073A AR 037490 A1 AR037490 A1 AR 037490A1
- Authority
- AR
- Argentina
- Prior art keywords
- compositions
- preparation
- fatty acid
- obesity
- kit
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000007787 solid Substances 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 4
- 229930195729 fatty acid Natural products 0.000 abstract 4
- 239000000194 fatty acid Substances 0.000 abstract 4
- -1 fatty acid salt Chemical class 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 238000002844 melting Methods 0.000 abstract 2
- 230000008018 melting Effects 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Position Fixing By Use Of Radio Waves (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01113792 | 2001-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037490A1 true AR037490A1 (es) | 2004-11-17 |
Family
ID=8177653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102073A AR037490A1 (es) | 2001-06-06 | 2002-06-04 | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6730319B2 (enExample) |
| EP (1) | EP1399153B1 (enExample) |
| JP (1) | JP4558313B2 (enExample) |
| KR (1) | KR100613946B1 (enExample) |
| CN (1) | CN1514726B (enExample) |
| AR (1) | AR037490A1 (enExample) |
| AT (1) | ATE375155T1 (enExample) |
| AU (1) | AU2002319189B2 (enExample) |
| BR (1) | BR0210267A (enExample) |
| CA (1) | CA2448035C (enExample) |
| DE (1) | DE60222898T2 (enExample) |
| DK (1) | DK1399153T3 (enExample) |
| ES (1) | ES2292782T3 (enExample) |
| GT (1) | GT200200105A (enExample) |
| MX (1) | MXPA03011041A (enExample) |
| PA (1) | PA8546501A1 (enExample) |
| PE (1) | PE20030262A1 (enExample) |
| PT (1) | PT1399153E (enExample) |
| UY (2) | UY3901U (enExample) |
| WO (1) | WO2002098413A2 (enExample) |
| ZA (1) | ZA200309099B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6616942B1 (en) * | 1999-03-29 | 2003-09-09 | Soft Gel Technologies, Inc. | Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| EP1175205B1 (en) * | 1999-11-12 | 2006-06-14 | Abbott Laboratories | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
| DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US8663687B2 (en) * | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| AU2002343555A1 (en) | 2001-11-14 | 2003-05-26 | Texas Tech University | Eutectic-based self-nanoemulsified drug delivery system |
| US8372430B2 (en) * | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
| ES2234393B2 (es) * | 2003-04-29 | 2006-09-01 | Laboratorios Belmac, S.A. | "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido". |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| PT1673359E (pt) * | 2003-09-12 | 2009-10-06 | Ranbaxy Lab Ltd | Processo para a preparação de formas cristalinas de orlistat |
| WO2005032278A1 (en) | 2003-09-29 | 2005-04-14 | Soft Gel Technologies, Inc. | SOLUBILIZED CoQ-10 |
| US8124072B2 (en) | 2003-09-29 | 2012-02-28 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
| JP4954450B2 (ja) * | 2004-06-14 | 2012-06-13 | ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス | 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導 |
| KR100669497B1 (ko) * | 2005-08-17 | 2007-01-16 | 보람제약주식회사 | 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법 |
| WO2008000440A1 (en) * | 2006-06-27 | 2008-01-03 | Lipid Nutrition B.V. | Use of a polyunsaturated fatty acid compound |
| US8343541B2 (en) | 2007-03-15 | 2013-01-01 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic acid compositions |
| EA201070378A1 (ru) * | 2007-09-17 | 2010-08-30 | Др. Редди`С Лабораторис Лтд. | Фармацевтические составы орлистата |
| US20100317642A1 (en) * | 2007-10-15 | 2010-12-16 | Inventis Dds Pvt Limited | Pharmaceutical composition of orlistat |
| US8298583B2 (en) * | 2007-10-19 | 2012-10-30 | Monosol Rx, Llc | Film delivery system for tetrahydrolipstatin |
| PL216542B1 (pl) | 2008-03-20 | 2014-04-30 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku |
| KR200449701Y1 (ko) * | 2008-08-21 | 2010-08-02 | 한복순 | 월풀욕조의 잔물 제거장치 |
| US8309107B2 (en) * | 2008-10-06 | 2012-11-13 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
| BRPI0901602B8 (pt) | 2009-04-03 | 2021-05-25 | Ems S/A | formulação farmacêuticas |
| US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
| KR101593539B1 (ko) * | 2015-07-03 | 2016-02-15 | 고려대학교 산학협력단 | 지방조직 중성지질 분해 효능을 가지는 아젤라산 조성물 |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| CN122182527A (zh) | 2016-05-05 | 2026-06-12 | 阿奎斯蒂弗医疗股份有限公司 | 增强递送的肾上腺素组合物 |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US10786475B2 (en) | 2018-02-20 | 2020-09-29 | Korea University Research And Business Foundation | Method for preventing, treating, or improving fatty liver by administering effective amounts of azelaic acid to a subject |
| US11931330B2 (en) | 2018-02-20 | 2024-03-19 | Korea University Research And Business Foundation | Composition for promoting skeletal muscle activity via induction of mitochondrial biogenesis comprising of azelaic acid as an active ingredient |
| CN108354910A (zh) * | 2018-05-17 | 2018-08-03 | 安士制药（中山）有限公司 | 一种西甲硅油软胶囊 |
| CN113163810A (zh) * | 2018-12-06 | 2021-07-23 | 国际香料和香精公司 | 用于调节味道的愈伤酸组合物和方法 |
| WO2020118002A1 (en) * | 2018-12-06 | 2020-06-11 | International Flavors & Fragrances Inc. | Boehmeria nivea compositions and methods for taste modulation |
| US20220287345A1 (en) * | 2019-08-08 | 2022-09-15 | Evonik Operations Gmbh | Solubility enhancement of poorly soluble actives |
| CN116490174A (zh) * | 2020-10-26 | 2023-07-25 | 莫纳什大学 | 淋巴靶向制剂 |
| WO2023076281A1 (en) | 2021-10-25 | 2023-05-04 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3013839A1 (de) | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
| DE3217071A1 (de) | 1982-05-06 | 1983-11-10 | Rüdiger Dr. 6365 Rosbach Gröning | Arzneimittel fuer die perorale applikation mit verbesserter biologischer verfuegbarkeit der wirkstoffe |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| FI912955A7 (fi) | 1990-06-25 | 1991-12-26 | Res Foundation For Mental Hygiene | Antimikrobiset rasvahappokoostumukset |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| JP2682353B2 (ja) * | 1991-11-20 | 1997-11-26 | 武田薬品工業株式会社 | 経口用医薬組成物およびその製造法 |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| JPH1081621A (ja) * | 1996-04-01 | 1998-03-31 | Takeda Chem Ind Ltd | 経口投与用医薬組成物 |
| DE19739031A1 (de) | 1997-09-05 | 1999-03-11 | Suwelack Nachf Dr Otto | Mittel zur peroralen Verabreichung, seine Herstellung und Verwendung |
| GB9727131D0 (en) | 1997-12-24 | 1998-02-25 | Knoll Ag | Therapeutic agents |
| CA2340056C (en) | 1998-08-14 | 2007-01-09 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors |
| GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
| AR025609A1 (es) | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
| AR025587A1 (es) | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones en dispersion que contienen inhibidores de lipasa |
| US6348492B1 (en) | 1999-10-29 | 2002-02-19 | 2Pro Chemical | Oxetanone derivatives |
| WO2001032670A1 (en) | 1999-10-29 | 2001-05-10 | John Jason Gentry Mullins | Oxetanone derivatives |
| WO2001032031A2 (en) * | 1999-11-04 | 2001-05-10 | Monsanto Technology Llc | Cholesterol reducing sterol compositions, preparation and method of use |
-
2002
- 2002-05-23 US US10/154,554 patent/US6730319B2/en not_active Expired - Lifetime
- 2002-05-29 UY UY3901U patent/UY3901U/es not_active Application Discontinuation
- 2002-05-31 EP EP02748725A patent/EP1399153B1/en not_active Expired - Lifetime
- 2002-05-31 CA CA002448035A patent/CA2448035C/en not_active Expired - Lifetime
- 2002-05-31 MX MXPA03011041A patent/MXPA03011041A/es active IP Right Grant
- 2002-05-31 AU AU2002319189A patent/AU2002319189B2/en not_active Expired
- 2002-05-31 DK DK02748725T patent/DK1399153T3/da active
- 2002-05-31 KR KR1020037015864A patent/KR100613946B1/ko not_active Expired - Lifetime
- 2002-05-31 WO PCT/EP2002/005958 patent/WO2002098413A2/en not_active Ceased
- 2002-05-31 BR BR0210267-6A patent/BR0210267A/pt not_active Application Discontinuation
- 2002-05-31 DE DE60222898T patent/DE60222898T2/de not_active Expired - Lifetime
- 2002-05-31 JP JP2003501452A patent/JP4558313B2/ja not_active Expired - Lifetime
- 2002-05-31 CN CN028114981A patent/CN1514726B/zh not_active Expired - Lifetime
- 2002-05-31 AT AT02748725T patent/ATE375155T1/de active
- 2002-05-31 PT PT02748725T patent/PT1399153E/pt unknown
- 2002-05-31 ES ES02748725T patent/ES2292782T3/es not_active Expired - Lifetime
- 2002-06-03 PA PA20028546501A patent/PA8546501A1/es unknown
- 2002-06-04 AR ARP020102073A patent/AR037490A1/es not_active Application Discontinuation
- 2002-06-05 PE PE2002000471A patent/PE20030262A1/es not_active Application Discontinuation
- 2002-06-05 UY UY27320A patent/UY27320A1/es not_active Application Discontinuation
- 2002-06-05 GT GT200200105A patent/GT200200105A/es unknown
-
2003
- 2003-11-21 ZA ZA2003/09099A patent/ZA200309099B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200309099B (en) | 2005-05-25 |
| PA8546501A1 (es) | 2003-01-24 |
| ES2292782T3 (es) | 2008-03-16 |
| UY27320A1 (es) | 2003-02-28 |
| US20030039686A1 (en) | 2003-02-27 |
| KR100613946B1 (ko) | 2006-08-18 |
| CN1514726A (zh) | 2004-07-21 |
| JP4558313B2 (ja) | 2010-10-06 |
| KR20040010681A (ko) | 2004-01-31 |
| CN1514726B (zh) | 2010-10-06 |
| EP1399153A2 (en) | 2004-03-24 |
| US6730319B2 (en) | 2004-05-04 |
| PE20030262A1 (es) | 2003-03-19 |
| CA2448035C (en) | 2009-11-03 |
| DK1399153T3 (da) | 2008-01-07 |
| ATE375155T1 (de) | 2007-10-15 |
| UY3901U (es) | 2002-07-31 |
| AU2002319189B2 (en) | 2005-08-18 |
| DE60222898T2 (de) | 2008-07-24 |
| EP1399153B1 (en) | 2007-10-10 |
| WO2002098413A2 (en) | 2002-12-12 |
| BR0210267A (pt) | 2004-07-20 |
| GT200200105A (es) | 2003-02-26 |
| PT1399153E (pt) | 2007-12-31 |
| MXPA03011041A (es) | 2004-03-19 |
| WO2002098413A3 (en) | 2003-02-27 |
| DE60222898D1 (de) | 2007-11-22 |
| CA2448035A1 (en) | 2002-12-12 |
| JP2004532272A (ja) | 2004-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27320A1 (es) | Nuevas composiciones farmacéuticas | |
| NO2025027I1 (no) | Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget. | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| BR9808888A (pt) | Formas de dosagem e método de melhorar disfunção erétil masculina | |
| CO5680109A1 (es) | Compuestos para el tratamiento de la disfuncion sexual femenina | |
| BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| ES2194732T3 (es) | Composiciones farmaceuticas orales de liberacion controlada de mesalazina. | |
| BR9406363A (pt) | Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico | |
| DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
| EP1354590A4 (en) | MEDICINES AGAINST JOINT DEFECTS | |
| AR033688A1 (es) | Composicion parenteral reconstituible | |
| BG106439A (en) | Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative | |
| WO2005065646A3 (en) | Novel drug compositions and dosage forms | |
| AR045906A1 (es) | Composicion farmaceutica para mejorar la solubilidad de farmacos hidrofobicos | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR0107564A (pt) | Composição de gliburida | |
| NO20034863L (no) | Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser | |
| CY1107819T1 (el) | Φαρμακευτικη διαμορφωση της ολανζαπινης | |
| BR0107899A (pt) | Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida | |
| AR036085A1 (es) | Formas de dosificacion y procedimiento para su fabricacion | |
| MXPA05008403A (es) | Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion. | |
| SE0000303D0 (sv) | Novel compounds | |
| EA200500175A1 (ru) | Соль морфин-6-глюкуронида | |
| MXPA04005033A (es) | Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |